Get news on conferences, trials, symposium invites, and more. Sign up for updates
Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative
Online education and training
Order products online
Reimbursement resources
Return a product
Customer support

Call customer care

1 (888) 272-1001

TheraSphere Y-90 Glass Microsphere glowing against blue background. TheraSphere sphere on blue background

TheraSphere™ Y-90 Glass Microspheres

Control for durable outcomes

TheraSphere is a targeted radioembolization therapy made of glass microspheres containing radioactive Yttrium-90 (Y-90). Designed for control to achieve durable patient outcomes, TheraSphere preserves quality of life and provides reproducible results for treating and referring physicians. As an FDA-approved Y-90 therapy for HCC, it is a cost-effective procedure backed by committed support from the industry leader, Boston Scientific.

Learn more about TheraSphere
Contact us

Any day dosing is here.

More days. More options. More control.

Deliver a proven dose, any day of the week. Introducing Any Day Dosing, powered by TheraSphere 360. More options to follow Dosimetry Steering Committee recommendations means you have more control to treat on your timeline. No compromises, no added products or processes. The same TheraSphere — ready when you are.

Already using TheraSphere 360? Talk to your TheraSphere Consultant for more information on Any Day Dosing.

New to TheraSphere 360? Request a live demo

Durability leads to quality of life

Confidently destroy tumor cells with proven ablative dosing and a good patient safety profile.1

View clinical data
icon-person-with-medical-symbol.

Referring physicians

Cancer care is multidisciplinary. TheraSphere is a minimally invasive, well-tolerated interventional treatment for your patients with hepatocellular carcinoma. It provides proven tumor control with predictable outcomes that helps maintain patients' quality of life, while preserving future treatment options.² 

 

View referring physician information
icon-truck

Get started with TheraSphere

Order TheraSphere using TheraSphere Now, a cloud-based website that facilitates personalized treatment order submission, tracking and order management. Increase treatment flexibility with expedited delivery of ready-to-deploy doses.

Order TheraSphere

Reimbursement

Find coding and economic resources for health care practitioners and their partners.

See reimbursement resources

References

  1. LEGACY: Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819. Percentage shown reflects patients who were eligible for tumor response assessment.
  2. Pasciak, A. S., Abiola, G., Liddell, R. P., Crookston, N., Besharati, S., Donahue, D., Thompson, R. E., Frey, E., Anders, R. A., Dreher, M. R., & Weiss, C. R. (2019). The number of microspheres in Y-90 radioembolization directly affects normal tissue radiation exposure. European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 816–827. https://doi.org/10.1007/s00259-019-04588-x.

*Refers to HCC or associated tumors .

TheraSphere indications, safety, and warnings
TheraSphere 360 indications, safety, and warnings

TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.